Skip to main content
. 2023 Aug 17;20:42. doi: 10.1186/s12979-023-00368-2

Table 1.

Baseline characteristics of the study participants

Healthcare workers
(N = 21)
Outpatients
 (N = 29)
Residents of long-term care facilities
 (N = 64)
P-value a)
Age, years, (IQR) 51.0 (42.0–60.0) 72.0 (67.0–76.0) 89.5 (84.0–93.5)  < 0.001
Age group, years, n (%)
 < 45 8 (38.1) 0 (0.0) 0 (0.0)  < 0.001
 45 to < 65 9 (42.9) 5 (17.2) 2 (3.1)
 65 to < 85 4 (19.0) 23 (79.3) 15 (23.4)
 ≥ 85 0 (0.0) 1 (3.5) 47 (73.4)
Sex, no. (%)
 Male 7 (33.3) 23 (79.3) 16 (25.0)  < 0.001
 Female 14 (66.7) 6 (20.7) 48 (75.0)
Body mass index, (IQR) 21.8 (20.9–23.2) 22.8 (20.7–24.2) 19.4 (17.4–21.1)  < 0.001
ECOG-PS, n (%)
 0 21 (100.0) 22 (75.9) 0 (0.0)  < 0.001
 1 0 (0.0) 7 (24.1) 0 (0.0)
 2 0 (0.0) 0 (0.0) 8 (12.5)
 3 0 (0.0) 0 (0.0) 17 (26.6)
 4 0 (0.0) 0 (0.0) 39 (60.9)
Comorbidity, n (%)
 Chronic respiratory diseases 0 (0.0) 26 (89.7) 10 (15.6)  < 0.001
 Chronic heart diseases 0 (0.0) 1 (3.4) 19 (29.7)  < 0.001
 Chronic liver diseases 0 (0.0) 2 (6.9) 3 (4.7) 0.493
 Chronic kidney disease 2 (9.5) 13 (44.8) 29 (45.3) 0.010
 Cerebrovascular diseases 1 (4.8) 3 (10.3) 28 (43.8)  < 0.001
 Hypertension 6 (28.6) 14 (48.3) 36 (56.3) 0.088
 Diabetes mellitus 1 (4.8) 8 (27.6) 14 (21.9) 0.122
 Solid cancer 0 (0.0) 4 (13.8) 5 (7.8) 0.203
 Leukemia 0 (0.0) 0 (0.0) 0 (0.0) NC
 Lymphoma 0 (0.0) 0 (0.0) 2 (3.1) 0.451
 Acquired immunodeficiency syndrome 0 (0.0) 0 (0.0) 0 (0.0) NC
 Connective tissue diseases 1 (4.8) 1 (3.4) 0 (0.0) 0.256
Immunosuppression b) 1 (4.8) 2 (6.9) 5 (7.8) 0.893
No. of Comorbidities, n (%)
 0 13 (61.9) 0 (0.0) 0 (0.0)  < 0.001
 1 5 (23.8) 6 (20.7) 6 (9.4)
 2 3 (14.3) 10 (34.5) 17 (26.6)
 ≥ 3 0 (0.0) 13 (44.8) 41 (64.1)
Functional Independence Measure, (IQR)
 Motor function 91.0 (91.0–91.0) 91.0 (91.0–91.0) 16.5 (13.0–45.0)  < 0.001
 Cognitive function 35.0 (35.0–35.0) 35.0 (35.0–35.0) 15.0 (7.0–23.5)  < 0.001
 Total score 126.0 (126.0–126.0) 126.0 (126.0–126.0) 30.5 (21.0–64.5)  < 0.001
Mini-mental State Examination, (IQR) 30.0 (30.0–30.0) 27.0 (26.0–30.0) 7.0 (0.0–15.0)  < 0.001
Laboratory data, (IQR)
 Serum total protein level (g/dL) 7.5 (7.2–7.6) 7.0 (6.7–7.3) 6.6 (6.3–7.2)  < 0.001
 Serum albumin level (g/dL) 4.6 (4.5–4.8) 4.2 (4.1–4.3) 3.6 (3.3–3.9)  < 0.001
 Serum cholesterol (mg/dL) 211.0 (194.0–234.0) 198.0 (171.0–212.0) 165.0 (142.0–190.5)  < 0.001
 WBC /mm3 5600 (4900–7000) 5670 (4790–6520) 5050 (4045–6645) 0.214
 Lymphocyte (%) 32.0 (26.0–36.0) 28.1 (24.2–32.4) 26.1 (19.6–32.0) 0.007
 Hemoglobin (g/dL) 14.0 (12.2–14.6) 13.5 (12.8–14.6) 11.1 (10.0–12.7)  < 0.001
 Platelet (× 104/μL) 21.0 (17.2–24.6) 20.7 (15.3–24.5) 19.9 (16.1–26.2) 0.873
 Total bilirubin (mg/dL) 0.6 (0.5–0.7) 0.7 (0.4–0.8) 0.4 (0.3–0.6)  < 0.001
 AST (U/L) 20.0 (18.0–27.0) 23.0 (19.0–31.0) 21.0 (18.5–28.0) 0.357
 ALT (U/L) 16.0 (14.0–23.0) 20.0 (16.0–31.0) 15.0 (11.0–22.0) 0.014
 LDH (U/L) 168.0 (144.0–180.0) 192.0 (173.0–222.0) 161.0 (141.5–186.5)  < 0.001
 e-GFR (mL/min per 1·73 m2) 78.6 (68.6–83.7) 61.3 (55.0–75.7) 65.3 (49.7–94.3) 0.071
 HbA1c (%) 5.6 (5.5–5.8) 6.0 (5.6–6.4) 5.4 (5.2–5.8)  < 0.001

Abbreviations: IQR Interquartile range, ECOG-PS Eastern Cooperative Oncology Group Performance Status Scale, WBC White blood cell count, AST Aspartate aminotransferase, ALT Alanine transaminase, LDH Lactate dehydrogenase, e-GFR Estimated glomerular filtration rate, HbA1c Glycated hemoglobin, NC Not calculable

a Kruskal–Wallis test for continuous variables and Fisher's exact test for categorical variables

b Immunosuppression included being on steroids, immunosuppressive agents, chemotherapy, or biologic therapy